Lee's Pharmaceutical Gains China Rights To Labor-Inducing Drug

   Date:2014/02/21     Source:

Lee’s Pharma has in-licensed China Rights to tafoxiparin, a clinical-stage product from Dilafor AB of Sweden. Tafoxiparin is a heparin derivative that has completed a Phase II trial as a treatment to induce labor. Lee’s will be responsible for conducting Phase II and III trials of the drug in China. Specific financial terms of the deal were not disclosed.

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号